| Literature DB >> 34140006 |
Louise Rose1, Lisa Burry2,3, Meera Agar4, Bronagh Blackwood5, Noll L Campbell6, Mike Clarke7, John W Devlin8, Jacques Lee9, John C Marshall10, Dale M Needham11, Najma Siddiqi12, Valerie Page13.
Abstract
BACKGROUND: Trials of interventions to prevent or treat delirium in adults in an acute hospital setting report heterogeneous outcomes. Our objective was to develop international consensus among key stakeholders for a core outcome set (COS) for future trials of interventions to prevent and/or treat delirium in adults with an acute care hospital admission and not admitted to an intensive care unit.Entities:
Keywords: Clinical trials; Core outcome set; Delirium; Hospitalization
Mesh:
Year: 2021 PMID: 34140006 PMCID: PMC8211534 DOI: 10.1186/s12916-021-02015-3
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Fig. 1PRISMA flow diagram
Systematic review study characteristics
| n (%) | |
|---|---|
| Study design | |
| RCT | 128 (70) |
| Before and after intervention study | 29 (16) |
| Non-randomized controlled trial | 19 (10) |
| Othera | 7 (4) |
| Study region | |
| North America | 58 (32) |
| Europe | 52 (28) |
| Asia | 50 (27) |
| Oceania | 15 (8) |
| Euroasia | 5 (3) |
| South America | 2 (1) |
| Multiple | 1 (1) |
| Study population | |
| Adults only | 183 (100) |
| Older adults only | 150 (88) |
| Patient type | |
| Surgical | 109 (60) |
| Medical | 68 (37) |
| Both | 6 (3) |
| Delirium as a study objective | |
| Primary | 137 (75) |
| Secondary | 46 (25) |
| Study intervention aim | |
| Prevention only | 125 (68) |
| Treatment only | 18 (10) |
| Both | 44 (22) |
| Study intervention | |
| Pharmacological agent to prevent and/or treat delirium | 87 (48) |
| Protocol or bundle to prevent and/or treat delirium | 80 (44) |
| Non-pharmacological to prevent and/or treat delirium | 16 (9) |
aOther comprised: 5 interventional cohort studies with controls, 1 quasi RCT, and 1 interrupted time series study
Percentages may not sum to 100 due to rounding
Outcomes identified by delirium survivor and family interview participants
| Outcome ( | n (%) |
|---|---|
| Emotional distress (i.e., fear and anxiety related to delirium symptoms) | 9 (50) |
| Delirium severity (i.e., severity of hallucinations, paranoid thoughts, delusions, disorientation) | 9 (50) |
| Ability to get back to previous cognitive abilities/long term cognitive outcomes | 8 (44) |
| Agitation—occurrence and durationa | 8 (44) |
| Safety—falls and other injuries, pulling out lines | 8 (44) |
| Ability to live alone independently/manage activities of daily living | 7 (39) |
| Being able to mobilize/physical functioning after discharge | 7 (39) |
| Risk factors for delirium including environmental factorsb | 6 (33) |
| Delirium duration | 5 (28) |
| Repeated infection as a risk factor for deliriumb | 5 (28) |
| Delirium reoccurrence and its risk factorsb | 5 (28) |
| Sleep quantity and quality | 5 (28) |
| Quality of life/recovery (physical and psychological) | 5 (28) |
| Acute stress and post-traumatic stress disorder | 4 (22) |
| Impact of delirium on family (stress, emotional wellbeing, burden)a | 4 (22) |
| Length of stay | 3 (17) |
| Mortality/survival | 3 (17) |
| Use of chemical restraint/psychotropic drugs | 3 (17) |
| Pain | 3 (17) |
| Discharge disposition including ability to be discharged home | 3 (17) |
| Time to/frequency of mobilization | 3 (17) |
| Use of physical restraint | 2 (11) |
| Ability to return to previous lifestyle/workc | 2 (11) |
| Time to delirium diagnosis | 2 (11) |
| Depression | 1 (6) |
| Sedative dose | 1 (6) |
| Delirium incidence | 1 (6) |
| Delirium resolution | 1 (6) |
| Subsyndromal deliriumc | 1 (6) |
| Hospital readmission | 1 (6) |
aIdentified in systematic review but reported in < 5% of studies
bConsidered as not an outcome during adjudication processes
cNot identified in systematic review
Round 1 Delphi participants
| ( | n (%) |
|---|---|
| Country of residence | |
| USA | 41 (37) |
| UK | 21 (19) |
| Australia and New Zealand | 20 (18) |
| Europe | 11 (10) |
| Canada | 11 (10) |
| South America | 3 (3) |
| Asia/Middle East | 3 (3) |
| Involvement with delirium | |
| Research and clinical work | 73 (66) |
| Clinical work only | 17 (15) |
| Delirium survivors and family members | 15 (14) |
| Research work only | 5 (5) |
| Profession of healthcare profession participants (N = 90) | |
| Physician | 66 (73) |
| Nurse or nurse practitioner | 14 (16) |
| Other healthcare profession | 6 (7) |
| Physio, respiratory, or occupational therapist | 4 (4) |
| Years of clinical experience (N = 90) | |
| > 10 | 73 (81) |
| 6–10 | 13 (14) |
| 3–5 | 4 (4) |
Round 2 Delphi scores
| Outcomes | Overall | Survivor/family (N = 7) | Clinician (N = 42) | Researcher (N = 28) | |
|---|---|---|---|---|---|
| Mean (SD) | % critical | % critical | % critical | % critical | |
| Delirium occurrence | 8.6 (0.8) | 97 | 86 | 98 | 100 |
| Delirium duration | 8.0 (1.0) | 95 | 86 | 95 | 96 |
| Adverse events/side effects | 8.0 (1.0) | 95 | 86 | 97 | 93 |
| Mortality | 8.3 (1.0) | 93 | 100 | 90 | 96 |
| Cognitive status | 8.1 (1.0) | 92 | 100 | 88 | 96 |
| Delirium severity | 8.0 (1.0) | 92 | 100 | 93 | 89 |
| Delirium resolution | 7.7 (1.1) | 87 | 71 | 93 | 82 |
| Agitation | 7.5 (1.2) | 87 | 100 | 92 | 75 |
| Use of antipsychotics/other medication for agitation | 7.6 (1.3) | 84 | 86 | 88 | 79 |
| Activities of daily living | 7.7 (1.2) | 83 | 71 | 88 | 86 |
| Patient emotional wellbeing | 7.5 (1.1) | 82 | 100 | 85 | 71 |
| Sleep | 7.4 (1.3) | 81 | 100 | 85 | 70 |
| Hospital disposition | 7.6 (1.3) | 80 | 71 | 80 | 71 |
| Falls and other injuries | 7.6 (1.4) | 80 | 100 | 80 | 75 |
| Physical restraint | 7.4 (1.6) | 79 | 86 | 88 | 64 |
| Physical functioning | 7.3 (1.2) | 78 | 71 | 78 | 79 |
| Delirium reoccurrence | 7.4 (1.3) | 78 | 86 | 83 | 68 |
| Length of stay | 7.4 (1.3) | 78 | 86 | 81 | 71 |
| Hospital readmission | 7.3 (1.4) | 75 | 71 | 76 | 75 |
| Health-related quality of life | 7.2 (1.2) | 75 | 100 | 83 | 57 |
| Sedation score/level indicating quality of sedation | 7.1 (1.5) | 73 | 86 | 74 | 67 |
| New onset dementia | 7.0 (1.6) | 71 | 100 | 64 | 71 |
| Costs | 7.0 (1.4) | 64 | 57 | 67 | 61 |
| Caregiver burden | 6.8 (1.4) | 61 | 71 | 66 | 50 |
| Pain score/level indicating quality of analgesia | 6.8 (1.5) | 58 | 86 | 60 | 48 |
| Pressure ulcers | 6.7 (1.3) | 52 | 71 | 53 | 46 |
| Delirium type | 6.5 (1.5) | 50 | 86 | 44 | 50 |
| Analgesic drug use | 6.6 (1.5) | 49 | 71 | 50 | 41 |
| Ability to participate in rehab | 6.5 (1.7) | 48 | 71 | 46 | 46 |
| Pneumonia | 6.7 (1.4) | 45 | 71 | 43 | 43 |
| Time to delirium onset | 6.3 (1.6) | 45 | 86 | 54 | 21 |
| Patient/family satisfaction | 6.3 (1.5) | 40 | 86 | 49 | 14 |
| Workload | 6.1 (1.6) | 40 | 83 | 41 | 25 |
| Study intervention related process outcomes | 6.2 (1.4) | 39 | 29 | 37 | 36 |
| Use of sitters | 6.0 (1.6) | 39 | 71 | 36 | 30 |
| Family emotional wellbeing | 6.2 (1.3) | 36 | 71 | 49 | 7 |
| Nutritional status | 6.0 (1.6) | 36 | 71 | 32 | 32 |
| Staff satisfaction | 5.7 (1.7) | 32 | 71 | 26 | 25 |
| Incontinence | 5.8 (1.4) | 31 | 43 | 33 | 25 |
Fig. 2Development of COS for trials of interventions to prevent or treat delirium in hospitalized adults